Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial

被引：0
|
作者：
Jin, Y. [1 ]
Yu, X. [1 ]
Fan, Y. [1 ]
He, X. Q. [1 ]
Lin, C. [1 ]
Hong, W. [1 ]
Gu, C. [1 ]
机构：
[1] Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
497P
引用
收藏
页码：S1656 / S1657
页数：2
相关论文
共 50 条
  • [31] Anlotinib plus everolimus as first-line treatment for advanced non-clear cell renal cell carcinoma: A single-center, single-arm, phase II trial
    Zhang, Hailiang
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in patients with potentially resectable NSCLC: An open-label, single-arm, phase II trial
    Zhu, X.
    Sun, L.
    Song, N.
    Sun, F.
    Yang, J.
    Duan, L.
    Zhao, D.
    He, W.
    Luo, J.
    Zhang, H.
    Wu, C.
    Zhu, Y.
    Zhang, P.
    Jiang, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S942 - S942
  • [33] Anlotinib combination with docetaxol for patients with previously treated advanced non-small cell lung cancer: A phase II, single-arm trial
    Chen, X.
    Shen, J.
    Li, X.
    Yang, S.
    Xia, B.
    Wang, B.
    Wang, J.
    Zheng, S.
    Zhao, P.
    Ma, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S877 - S877
  • [34] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Qin, Yan-ru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 340 - 340
  • [35] Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Wang, Zhan
    Liu, Ke
    Wu, Ying
    Ling, Yan
    Chen, Shi-Qi
    Zhong, Xue
    Duan, Xiao-Peng
    Qin, Wen-Xing
    Xue, Lei
    Guo, Zhen-Hong
    Zang, Yuan-Sheng
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 815 - 825
  • [36] A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
    Wu, L.
    Chen, B.
    Yao, W.
    Li, X.
    Xiao, Z.
    Liu, H.
    Kong, Y.
    Liu, L.
    Xu, Y.
    Wang, Q.
    Li, J.
    Xu, F.
    Xu, L.
    Li, K.
    Song, W.
    Li, B.
    Wang, Z. M.
    Xia, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S1006 - S1006
  • [37] Updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer
    Xu, M.
    Pu, Y.
    Jiang, Y.
    Liu, H.
    Feng, Y.
    Qian, C.
    Dai, N.
    Li, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S866 - S866
  • [38] First Line Combination of Toripalimab and Chemotherapy in Advanced Thymic Carcinoma: A Single-Center, Prospective, Single-Arm, Phase II Trial
    Hu, X.
    Feng, Y.
    Zhu, H.
    Lu, J.
    Liu, Y.
    Xing, P.
    Wang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S331 - S331
  • [39] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Chang, Zhiwei
    Wang, Rui-Rui
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 367 - 367
  • [40] A phase II single-arm study of pazopanib and paclitaxel as first-line treatment for patients with advanced melanoma
    Fruehauf, John P.
    Alger, Beverly
    Jakowatz, James G.
    Hsiang, David
    Sender, Leonard S.
    Bettis, Claudette
    Casey, Cameron
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345